BUFFALO, NY -- (Marketwire) -- 09/30/09 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Joint Science and Technology Office for Chemical and Biological Defense at the Defense Threat Reduction Agency of the Department of Defense awarded the Armed Forces Radiobiology Research Institute (AFRRI) a $612,000 grant to study, with technical assistance from the Company, select compounds within Cleveland BioLabs's Protectan 600 series for development as a radiation countermeasure for treatment of acute radiation syndrome.

Michael Fonstein, Ph.D., Chief Executive Officer and President of Cleveland BioLabs, stated, "We have enjoyed successful collaborative relationships with both the Department of Defense and AFRRI and look forward to extending our collective efforts to further research on our 600 series of Protectan compounds."

Cleveland BioLabs's Protectan 600 series of compounds are proprietary synthetic agents that have demonstrated radioprotective and radiomitigating effects in animal studies. Research into the mechanism of action behind these effects has determined that the 600 series of compounds are powerful inducers of hematopoietic stem cells in bone marrow and mobilizers of these stem cells into peripheral blood.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at http://www.cbiolabs.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2009.

Rachel Levine
Director Corporate Development & Communications
Cleveland BioLabs, Inc.
T: (646) 284-9439
E: rlevine@cbiolabs.com